NGFR and melanoma: Our study indicates that while the percentages of NGFR-positive cells were uniformly increased after short treatment with vemurafenib or trametinib, not all melanoma cell populations resistant to either of these drugs showed higher frequency of NGFR-positive cells than their drug-naïve counterparts.